June 23, 2020

To

Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI ·400 051

Company Code No. AUROPHARMA

Dear Sir,

AURO BIND 0

To

The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI ·400 001

Company Code No. 524804

Sub: Submission of copies of notices published in Newspapers.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose notice for the attention of equity shareholders of the Company published on 23.06.2020, intimating that the equity shares in respect of which dividend remain unclaimed f:lr seven consecutive years, would be transferred to Investor Education and Protection Fund (IEPF), in the following newspapers.

• Business Standard (English daily) • Andhra Prabha (Telugu daily).

Kindly take the above information on record.

Yours faithfully, For AUROBINDO PHARMA LIMITED

r':::>.~ . . B.Adi Reddy Company Secretary

(CIN: l24239TG1986PlC015190) AUROBINDO PHARMA LIMITED

PAN No. t.ABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi·tech City, Kondapur, Hyderabad· 500 084 T.S., INDIA Tel : +91 406672 5000 /1200 =ax: +91 4067074059

Regd. Off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad· 500 038. T.S., INDIA Tel: +91 4023736370 Fax : +91 4023747340, Email: inf, @aurobindo.com

www.aurobindo.com

HYDERABAD | TUESDAY, 23 JUNE 2020 COMPANIES 3. <

Cadila-CSIR’s sepsis drug showspromise in fightagainst Covid-19Thedrug isall set togotophase3ofclinical trialsafter theearlierphaseshowedpositive resultsSOHINI DASMumbai,22June

A s the race to find treatment orvaccine for Covid-19 hots up,Ahmedabad-based CadilaPharmaceuticals and the Council ofScientific and Industrial Research’s(CSIR’s) Sepsivac is all set to enterPhase 3 clinical trials after the earlierphase showed positive results.

Thepublic-privatepartnership trial-generated data will be soon presentedbefore the country’s drug regulator tosee if it can get emergency-use autho-risation.

“By July 15, we will have the nec-essary data from the Phase 2 trialsand again approach the regulator tosee if this drug can be given emer-gency-use authorisation in the wakeof the pandemic.Meanwhile, we alsohave the approval in place to start twoPhase 3 trials— one on 600 patients,another on 500 patients — for thisdrug,” said Ram A Vishwakarma,director, CSIR-Indian Institute ofIntegrative Medicine.

The Phase 2 trials were conductedacross Postgraduate Institute ofMedical Education and Research,Chandigarh, All India Institute ofMedical Sciences (AIIMS) Delhi, andAIIMS, Bhopal. For the third phase,twomore siteswill be added—AIIMS

Raipur and a Banaras HinduUniversity institute.

Sepsivac is an immunomodulatordrug. Researchers feel the drug worksin a two-pronged approach. One, itkick-starts the innate immunity sys-temtoactagainst thepathogen.Two, italso works to reduce the release ofinflammatory Cytokine IL-6 that

attacks internal organs.Vishwakarma explained that

Sepsivac is not an antibody-generat-ing vaccine. “It can be called a thera-peutic vaccine that will kick-start theinnate immunity. There are two kindsof immunity in our body — innateimmunity that we are born with andget fromour ancestors and there is the

acquired immunity. Acquired immu-nity ismostlygovernedbyantibodies,”said Vishwakarma.

Wheneveravirusorbacteriaattacksour body, the innate immunity ortrained immunity first reacts. “We areboosting this trained immunityorwhatwecall scientifically,Th1 (Thelper type1). It reacts in most patients, which iswhy they get cured. In some withcomorbidities, their immunesystemisalready compromised,” saidVishwakarma.

Given in the early phase of infec-tion, it protects thepatient from infec-tion. The second way in which thisdrug works is by inhibiting the IL-6or inflammatory cytokine.

“Most of the damage happens dueto this in IL-6 in patients. A Rochedrug Tocilizumab works in this man-ner. Sepsivac orMycobateriumwalsostops the release of IL-6 which wouldcontrol the multi-organ damage. Apatient’s innate immunity then hasan opportunity to protect him,” heexplained. Mycobaterium w is not aSARS-CoV-2 (severe acute respirato-ry syndrome-coronavirus-2) virus-specific immunity.

Further, in thePhase3 trial, theplanis to give the drug to a group of 500patientsafter theyhaverecovered fromthevirus, so that theydonot redevelopthe disease in future.

54employeestestpositive,ONGChaltsopsat2rigsSHINE JACOBNewDelhi,22June

State-run Oil and Natural GasCorporation(ONGC)hashaltedoperationsattwodrillingrigsinWestern Coast, following thedeathofanemployeeandano-ther54testingpositiveforcoro-navirus(Covid-19).Thetworigsareintwoofthemost lucrativeassetsofthecompany—Mum-baiHighandBassein.

A company official saidwork stopped temporarilyonly at two rigs and theremaining 34 in the offshorewere operational. He addedthere was no impact on thecompany’s production.

Mumbai High, also knownasBombayHigh, isanoffshoreoilfield located in the ArabianSea, approximately 160 kmwestof theMumbaicoast.Thefield, discovered in 1974 andstarted production in 1976, isknownprimarilyfor itsoilpro-duction. It also consists of twoblocks – Mumbai High Northand Mumbai High South.Mumbai High producesaround 170,000 barrels of oilper day and 12 million metricstandard cubicmetres per day(mmscmd)ofnatural gas.

Ontheotherhand,Basseinfield, also called the Vasaifield, is located 80 km off theMumbai coast and is consid-ered one of the largest gasfields in India. The field wasdiscovered in 1976 and put inproduction in 1988. Spreadacross 7,300 square kilome-tres in theArabianSea, it con-sists of South Bassein field,NBP (D-1) field, B-193 supersour field,VasaiEast fieldandC-SeriesandDamangas field.Bassein field produces 32mmscmd of gas and 60,000barrels of oil per day.

ONGC claimed that worksaregoingonfollowingthestan-dard operating procedure andits staff is properly informedabout social distancing.Interestingly,ONGCemployeebodies had reportedly allegedthat the infection was spread-

ingduetolackofproperguide-lines.Duringthe lockdown, itsstaff inMumbaioffshorefieldswereworkingcontinuouslyforfiveweeks. Itwasonlyafterthelockdownrestrictionswerelift-eddidONGCarrange forchar-ter flights for their workers toreachMumbai.

The company’s overallproduction was hit badly bythe lockdowndueto theCovid19outbreak. InApril, thecom-pany’snatural gasproductiondropped by 15 per cent whileits crude oil productiondipped marginally by 0.5 percent compared to the samemonth in 2019.

Overall, gasoutputof Indiafor April also dropped 18.6 percentto2.16billioncubicmetres(bcm) against 2.65 bcm a yearago. Crude oil production alsofell 6.35 per cent to 2.5milliontonnes (mt) inApril.

The state-runmajor cut itscapital expenditure (capex) byover15percentor~5,000crorefor 2020-21. India’s largest oilandgasproducerhadbudgetedacapexof ~32,502crore for thefinancial year.

However, now it has beencuttoaround~27,500crore.Thecompany had also sought aprice assurance of $45 a barreloncrudeoil.

ClearTaxeyes foray intoSMElendingbizDEBASIS MOHAPATRABengaluru,22June

Online tax filing platformClearTax is considering foray-ing into the lending business,with an aimof tapping therising demand for loansamong small andmediumenterprises (SMEs) in theongoing financial year.

The Bengaluru-headquar-tered firmplans towork as amarketplace for originatingloans for SMEs through part-nershipwith lenders such asbanks andnon-bankingfinancial companies (NBFCs).

“Through our associationwith the SMEs, we haverealised that the access tocredit for SMEs is low.Because of theCovid-19 pandem-ic, businesses arein need of credit.So, we have starteda newdivision forthis,” said ArchitGupta, founderandCEO,ClearTax.

“We don’t haveour NBFC licence, so wewillbe partnering lenders fornow.”

Owing to Covid-inducedslowdown, the fintech firmhas seen drop in tax filing(GST) volume in the first 60

days ofthe lockdownperiod.

“Things arecoming back tonormal asmanybusinesses arereopening. Ourbusiness hasreached 70 percent of the pre-

Covid level andwe are hope-ful that thingswill be normalby September,” saidGupta.

The company, which hasextended its work fromhome(WFH) option for its employ-ees until September, said ithad gainedmarket share incomparison to its competi-tors in the tax filing space.

“There has been a rapidgrowth fromCA (charteredaccountant) side (of the busi-ness), especially fromareaslike Gujarat andMaharashtraas these are the regions,which have been affected alot. The number of CAs usingthis platformhas also goneup,” saidGupta.

He also said thatmany

enterprisesweremigrating toCloud because of the pan-demic, leading to addition ofnew clients.

In FY21, the companyexpects its growth tomoder-atemarginally, though it ishopeful of still logging 75 percent growth over the previousfinancial year.

In FY20, the companyexpanded its revenue by 100per cent. The company,which expects to reach break-even in the next 18months, isalso looking to increase itsheadcount in thisfinancial year.

Milkbasket gets$5.5 million infresh fundingOnlinegrocerydeliverystart-upMilkbaskethas raised$5.5million in a fresh fundinground, ledbyInflectionPointVentures, alongwithexistinginvestors. The company willuse the funding to grow itsoperationsacross India.

According toMilkbasket,its Gurugram, Noida andBengaluru operations arealready breaking even, withother citiesonanacceleratedtrack. With the latest round,thecompanyhassofarraised$33million.

SAMREENAHMAD

The companyexpects its growthto moderatemarginally, thoughit is hopeful oflogging 75%growth overthe previousfinancial year

Pricein~ON THE BSE

Sepsivacisusedtotreatsepsis,alife-threateninginfection

Ithasatwo-prongedapproach—boostsinnateimmunity&inhibits inflammatoryresponseofbody

Humanshaveinnateandacquiredimmunity.Sepsivackickstartstheinnateimmunityinaperson

Acquiredimmunityorconventionalvaccinesworkviaantibodies

Sepsivacisdifferentfromaconventionalvaccine

It inhibitsIL6or inflammatorycytokinesthatattacktheorgans

Iforgandamageiscontrolled,body’sinnateimmunitythenhelpsfightthevirus

WHAT IS SEPSIVAC

Printed and Published by GonapaNarayana on behalf of Business StandardPrivate Limited and printed at Eenadu

Press, Plot No : A1/1, Block No : 3, IndustrialDevelopment Area, Uppal, 500 039, Ranga

Reddy Dist.- Telangana andpublished at PTI Building, IIIrd Floor,A.C. Guards, Hyderabad-500 004

Editor : Shyamal Majumdar

RNI NO : AP ENG/2000/01017

Readers should write their feedback atfeedback@bsmail.in

Ph. 040-23375797 Fax :+91-40-23371863

For Subscription and Circulationenquiries please contact:

Ms. Mansi SinghHead-Customer Relations

Business Standard Private Limited.H/4 & I/3, Building H,Paragon Centre, Opp.

Birla Centurion, P.B.Marg, Worli,Mumbai - 400013

E-mail: subs_bs@bsmail.in“or sms, SUB BS to 57007”

DISCLAIMER News reports and featurearticles in Business Standard seek to presentan unbiased picture of developments in themarkets, the corporate world and thegovernment. Actual developments can turnout to be different owing to circumstancesbeyond Business Standard’s control andknowledge. Business Standard does not takeany responsibility for investment or businessdecisions taken by readers on the basis ofreports and articles published in thenewspaper. Readers are expected to form theirown judgement.Business Standard does not associate itselfwith or stand by the contents of any of theadvertisements accepted in good faith andpublished by it. Any claim related to theadvertisements should be directed to theadvertisers concerned.Unless explicitly stated otherwise, all rightsreserved by M/s Business Standard Pvt. Ltd.Any printing, publication, reproduction,transmission or redissemination of thecontents, in any form or by any means, isprohibited without the prior written consent ofM/s Business Standard Pvt. Ltd. Any suchprohibited and unauthorised act by anyperson/legal entity shall invite civil and

criminal liabilities.

No Air Surcharge

Business StandardHYDERABAD EDITION

ParticularsSr.No.

((`̀ in Lakhs))

Consolidated

Quarter Ended

Audited Audited

Year Ended

By Order of Board of DirectorsFor AIA Engineering Limited

Sd/-(Bhadresh K. Shah)Managing Director

DIN:00058177Place: AhmedabadDate: 22 June 2020

1 Total Income from Operations (Net) 85,693.42 88,799.22 298,087.75 306,949.99

2 Net Profit / (Loss) for the period (before Tax, Exceptional and/or

Extraordinary items) 18,574.66 19,025.02 71,872.43 69,440.01

3 Net Profit / (Loss) for the period before tax (after Exceptional and/or

Extraordinary items) 18,574.66 19,025.02 71,872.43 69,440.01

4 Net Profit / (Loss) for the period after tax (after Exceptional and/or

Extraordinary items) 14,242.22 15,589.32 59,032.01 51,143.77

5 Total Comprehensive Income for the period [Comprising Profit / (Loss)

for the period (after tax) and Other Comprehensive Income (after tax)] 16,325.26 16,925.76 58,638.31 50,490.47

6 Equity Share Capital 1,886.41 1,886.41

7 Reserves (excluding Revaluation Reserve) as per the Balance Sheet 368,242.23 349,484.40

8 Earnings Per Share(EPS) (of ` 2 each)

(for continuing and discontinued operations)

a. Basic 15.02 16.52 62.59 54.16

b. Diluted 15.02 16.52 62.59 54.16

Notes:1. The details of the following items on the Standalone basis:

AIA ENGINEERING LIMITEDRegd. Office.: Regd. Office.: 115, GVMM Estate, Odhav Road, Ahmedabad 382 410 CIN: L29259GJ1991PLC015182;

Ph. 079-22901078 Fax: 079-22901077; Website: www.aiaengineering.com, Email: ric@aiaengineering.com

Statement of Consolidated Audited Results for the Quarter andYear Ended 31st March, 2020

31/03/201931/03/202031/03/201931/03/2020

Audited Audited

ParticularsSr.No.

((`̀ in Lakhs))

QuarterEnded

Audited Audited

YearEnded

Total Income from Operations (Net) 71,192.40 74,006.23 258,762.44 283,758.50

Profit Before Tax 43,184.40 13,511.42 95,741.03 60,191.41

Profit After Tax 38,982.60 9,806.18 83,252.97 41,482.17

Total Comprehensive income for the period (after tax) 39,323.95 9,705.81 83,515.58 41,577.33

2 The above is an extract of the detailed format of Financial Results for the Quarter / Year ended 31st March, 2020 filed with the

Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The

full format of the Financial Result for the Quarter / Year ended 31st March, 2020 are available on the Stock Exchange website

(www.bseindia.com & www.nseindia.com) and Company's website (www.aiaengineering.com).

31/03/201931/03/202031/03/201931/03/2020

Audited Audited

CIN: L26942MH1983PLC265166RegdOffice: thA-610, Kanakia Wall Street, 6 Floor, Andheri Kurla Road,

Chakala Junction, Andheri (East), Mumbai-400093 Website: www.anjanicement.comTel No: 022-62396051 Email Id: secretarial@anjanicement.com

NOTICEPursuant to Regulation 29 read with Regulation 47 (1)(a) of the Securities and ExchangeBoard of India (Listing Obligations and Disclosure Requirements) Regulations, 2015,Notice is hereby given that a meeting of the Board of Directors of the Company isscheduled to be held on Monday, June 29, 2020 inter alia to consider and approve theAudited Financial Results of the Company for the quarter and Year endedMarch 31, 2020and to recommend a dividend, if any on the equity shares of the Company for the yearendedMarch 31, 2020.The said intimation will be available on the website of the Company atwww.anjanicement.com and on the website of the BSE Limited at andwww.bseindia.comNSELimited at .www.nseindia.com For Anjani Portland Cement Limited

Rohit TapariaCompany Secretary and Compliance Officer

(M.No: A35756)Place : MumbaiDate : June 22, 2020

Anjani Portland Cement Limited

eT+>∑fiȳês¡+ 23 pHé 2020 ôV’≤